Pemfexy Generic Name & Formulations
Metastatic nonsquamous non-small cell lung cancer (NSCC) with no EGFR or ALK genomic tumor aberrations, in combination with pembrolizumab and platinum chemotherapy as initial treatment. Locally advanced or metastatic nonsquamous NSCC: in combination with cisplatin as initial treatment, or as a single agent for maintenance in patients whose disease has not progressed after 4 cycles of platinum-based 1st-line chemotherapy. Treatment of patients with recurrent, metastatic nonsquamous NSCLC after prior chemotherapy, as a single agent. Malignant pleural mesothelioma: in combination with cisplatin, for the initial treatment of patients whose disease is unresectable or who are otherwise not candidates for curative surgery.
Limitations of Use
Pemfexy Dosage and Administration
Supplement with oral folic acid one week prior to 1st pemetrexed dose, continue during treatment, and for 21 days after the last dose. Supplement with intramuscular vitamin B12 one week prior to 1st pemetrexed dose and every 3 cycles thereafter. Pretreat with dexamethasone for 3 consecutive days, beginning the day before each pemetrexed dose. In combination regimens: give pemetrexed dose after pembrolizumab and prior to carboplatin or prior to cisplatin. CrCl ≥45mL/min: 500mg/m2 by IV infusion over 10mins on Day 1 of each 21-day cycle. In combination with pembrolizumab/platinum chemotherapy for NSCLC: treat for 4 cycles; after platinum-based therapy completion, give pemetrexed with/without pembrolizumab until disease progression or unacceptable toxicity. In combination with cisplatin for NSCLC: treat for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Maintenance, recurrent NSCLC, mesothelioma: continue until disease progression or unacceptable toxicity. Dose modifications: see full labeling.
Pemfexy Boxed Warnings
Pemfexy Adverse Reactions
Pemfexy Clinical Trials
Pemfexy Patient Counseling